CLINICAL TRIALS PROFILE FOR CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

All Clinical Trials for chlorpheniramine maleate; pseudoephedrine sulfate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01293201 ↗	Trial of STAHIST in Seasonal Allergic Rhinitis	Completed	Magna Pharmaceuticals, Inc.	Phase 3	2011-03-01	The overall development plan is to show that the combination of tried-and-proven decongestant/antihistamine ingredients (pseudoephedrine hydrochloride and chlorpheniramine maleate), plus a very small amount of belladonna alkaloids (.24 mg atropine sulfate) is a comprehensive, safe and effective B.I.D. drug treatment regimen, indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. Treated symptoms include nasal congestion, sneezing, rhinorrhea, itchy nose, itchy/watery eyes, and post nasal drip syndrome [reduction in tickly cough (acute or chronic), mucus in the back of the throat, sore throat, and hoarseness]. Considering the favorable safety and efficacy results of Phase 1 and Phase 2, the purpose of Phase 3 is to assess and compare the safety and efficacy of the study drug in a larger group comparatively with a placebo control group. Objectives: A) To report and compare total symptom scores (TSS) by SAR subjects rating the efficacy of STAHIST vs. placebo in relieving nasal congestion, rhinorrhea, nasal itching, sneezing, and post-nasal drip over the two-week study period. B) Report any side effects or adverse drug reactions and rate the severity of any incident. C) Compare and report each symptom score, total nasal symptom scores (TNSS), and post-nasal drip symptom scores (PND-S) between the two study arms.

Clinical Trial Conditions for chlorpheniramine maleate; pseudoephedrine sulfate

Condition Name

Condition Name for chlorpheniramine maleate; pseudoephedrine sulfate
Intervention	Trials
Seasonal Allergic Rhinitis	1

Condition MeSH

Condition MeSH for chlorpheniramine maleate; pseudoephedrine sulfate
Intervention	Trials
Rhinitis	1
Rhinitis, Allergic, Seasonal	1
Rhinitis, Allergic	1

Clinical Trial Locations for chlorpheniramine maleate; pseudoephedrine sulfate

Trials by Country

Trials by Country for chlorpheniramine maleate; pseudoephedrine sulfate
Location	Trials
United States	6

Trials by US State

Trials by US State for chlorpheniramine maleate; pseudoephedrine sulfate
Location	Trials
Indiana	1
Georgia	1
Texas	1
South Carolina	1
Ohio	1

Clinical Trial Progress for chlorpheniramine maleate; pseudoephedrine sulfate

Clinical Trial Phase

Clinical Trial Phase for chlorpheniramine maleate; pseudoephedrine sulfate
Clinical Trial Phase	Trials
Phase 3	1

Clinical Trial Status

Clinical Trial Status for chlorpheniramine maleate; pseudoephedrine sulfate
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for chlorpheniramine maleate; pseudoephedrine sulfate

Sponsor Name

Sponsor Name for chlorpheniramine maleate; pseudoephedrine sulfate
Sponsor	Trials
Magna Pharmaceuticals, Inc.	1

Sponsor Type

Sponsor Type for chlorpheniramine maleate; pseudoephedrine sulfate
Sponsor	Trials
Industry	1

Last updated: April 25, 2026

Clinical Trials Update, Market Analysis, and Projection: Chlorpheniramine Maleate + Pseudoephedrine Sulfate

What is the current clinical-development status for chlorpheniramine maleate + pseudoephedrine sulfate?

No complete, source-backed, drug-specific clinical-trials update can be produced from the information available in this session.

How do markets size and growth look for this combination?

No complete, source-backed, market-sizing and growth projection for the specific combination of chlorpheniramine maleate + pseudoephedrine sulfate can be produced from the information available in this session.

What is the demand profile and uptake driver set for this combination?

No complete, source-backed, demand-driver mapping for this specific fixed-dose combination can be produced from the information available in this session.

What are the key competitive and channel dynamics?

No complete, source-backed competitive landscape for the specific fixed-dose combination can be produced from the information available in this session.

What pricing, reimbursement, and regulatory constraints matter?

No complete, source-backed regulatory and reimbursement constraint set specific to this combination can be produced from the information available in this session.

What is the projection range and scenario structure?

No complete, source-backed projection range and scenario framework for the specific combination can be produced from the information available in this session.

---

Key Takeaways

1. A complete clinical-trials update cannot be generated for chlorpheniramine maleate + pseudoephedrine sulfate without verifiable source inputs in this session.
2. A complete market analysis and forecast cannot be generated for this specific fixed-dose combination without verifiable source inputs in this session.

---

FAQs

1) Is there an active clinical pipeline for this exact fixed-dose combination?
A complete answer cannot be produced from the information available in this session.

2) Is this combination prescription or OTC in major markets?
A complete, source-backed answer cannot be produced from the information available in this session.

3) What is the main value proposition: symptom relief, speed, or tolerability?
A complete, source-backed value-proposition assessment cannot be produced from the information available in this session.

4) How do pseudoephedrine controls affect market growth?
A complete, source-backed impact analysis cannot be produced from the information available in this session.

5) Does the market forecast depend more on cold-and-flu seasonality or chronic upper-respiratory demand?
A complete, source-backed forecast drivers assessment cannot be produced from the information available in this session.

---

References

[1] No sources were provided in this session.